ClinicalTrials.gg
CompletedNCT02616601Updated Jul 17, 2019Results posted

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

A Phase 3 interventional study of Generic Fluorouracil Cream and Carac® (Fluorouracil) Cream in Actinic Keratosis, sponsored by Actavis Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-17.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2015, registered Nov 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fluorouracil in Keratosis, Actinic — 3 open to participants now, 5 under way, 1 of them phase 3. Fluorouracil · Keratosis, Actinic.

Enrollment
4th of 19
422 · median 60
Started
2015
the only one that year
Phase 3
9 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
1 of 19
Actavis Inc.

Among the 19 studies testing fluorouracil in Keratosis, Actinic, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 9 in phase 3, and was the 11th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

3 of the 19 studies testing fluorouracil in Keratosis, Actinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing fluorouracil in Keratosis, Actinic, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.

Read the detailed description

This is a multicenter, double-blind, vehicle-controlled, parallel group comparison study of a generic fluorouracil cream, 0.5% and Carac (fluorouracil) Cream, 0.5% in participants with actinic keratoses on the full face or balding scalp.

03

Conditions studied

  • Actinic Keratosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is male and/or female, 18 years of age or older.
  • Participant is willing and able to give written .
  • Participant is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
  • Participant has a clinical diagnosis of actinic keratoses with at least 5 and no more than 10 clinically typical, visible or palpable, discrete, actinic keratoses (AK) lesions, each at least 4 millimeters (mm) in diameter on the face (excluding ears) or balding scalp.
  • Participant is in good general health and free of any disease state or physical condition that might impair evaluation of AK lesions or which, in the investigator's opinion, exposes the participant to an unacceptable risk by study participation.
  • Females must be , surgically sterile, or use an effective method of with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion criteria

Exclusion Criteria:

  • Participant is pregnant, lactating, or is planning to become pregnant during the study.
  • Participant is currently enrolled in an drug or device study.
  • Participant has used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
  • Participant has hyperkeratotic, hypertrophic, or large mat-like AK lesions (for example, an AK lesion >1 cm\^2 in size) within the treatment area.
  • Participant has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
  • Participant is (for example, (HIV), systemic , graft host disease)
  • Participant has experienced an unsuccessful outcome from previous topical fluorouracil therapy (an unsuccessful outcome is defined as after a reasonable therapeutic study with no compliance issues and the topical drug did not work).
  • Participant has a history of sensitivity to any of the ingredients in the test articles.
  • Participant has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.
  • Participant used topical creams, lotions, or gels of any kind within the selected treatment area within 1 day prior to entry into the study.
  • Participant has used topical medications; , alpha hydroxy acids (for example, glycolic acid, lactic acid, etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate; or prescription retinoids (for example, tazarotene, adapalene, tretinoin) within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
  • Participant has had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
  • Participant has used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within 1 month prior to the Baseline Visit.
  • Participant has had dermatologic procedures or surgeries such as: laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B therapy, chemical peels, or dermabrasion within the selected treatment area (face or balding scalp) within 6 months prior to the Baseline Visit.
  • Participant has lesions suspicious for skin cancer (skin cancer not ruled out by ) or untreated skin cancers within the selected treatment area (face or balding scalp).
  • Participant has any skin pathology or condition on the face or balding scalp that, in the Investigator's opinion, could interfere with the evaluation of the test article or requires the use of interfering topical, systemic, or surgical therapy.
  • Participant has any condition which, in the Investigator's opinion, would make it unsafe or preclude the participant's ability to fully participate in this research study.
  • Participant is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.
  • Participant is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (for example, due to alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator.
  • Participant has been previously enrolled in the same study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Generic Fluorouracil Cream

    Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.

    Drug: Generic Fluorouracil Cream

  • Active comparator
    Carac® (Fluorouracil) Cream

    Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.

    Drug: Carac® (Fluorouracil) Cream

  • Placebo comparator
    Vehicle Cream

    Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.

    Drug: Vehicle Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Success (Complete Clearance) at Week 6

    Percentage of participants with treatment success (complete clearance) at Week 6 (4 weeks after completion of 2 weeks of treatment). Complete clearance was defined as having no (zero) clinically visible actinic keratoses (AK) lesions in the treatment area at the Week 6/End Of Study visit. All AK lesions (baseline and new lesions) independent of size within the treatment area were treated and included in the efficacy lesion count.

    Time frame: Week 6

07

Results

Posted Jul 17, 2019

Participant flow

Participant flow — Overall Study
MilestoneGeneric Fluorouracil CreamCarac (Fluorouracil) CreamVehicle Cream
Started140140142
Safety population140140142
Mitt population137136138
Pp population112121123
Completed131136135
Not completed947
Withdrew: Withdrawal by subject443
Withdrew: Adverse event202
Withdrew: Death100
Withdrew: Lost to follow-up101
Withdrew: Non-compliance with test article101

Outcome measures

PrimaryPercentage of Participants With Treatment Success (Complete Clearance) at Week 6

Percentage of participants with treatment success (complete clearance) at Week 6 (4 weeks after completion of 2 weeks of treatment). Complete clearance was defined as having no (zero) clinically visible actinic keratoses (AK) lesions in the treatment area at the Week 6/End Of Study visit. All AK lesions (baseline and new lesions) independent of size within the treatment area were treated and included in the efficacy lesion count.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Success (Complete Clearance) at Week 6
percentage of participantsGeneric Fluorouracil CreamCarac (Fluorouracil) CreamVehicle Cream
Percentage of Participants With Treatment Success (Complete Clearance) at Week 633.933.93.3
Statistical analysis
  • Generic Fluorouracil Cream vs Carac (Fluorouracil) Cream · Mean difference (net): 0.04 · 90% CI -11.03 to 11.1190% Wald's confidence interval with a continuity correction for the difference (Generic Fluorouracil Cream - Carac \[Fluorouracil\] Cream) in complete clearance rates.
  • Generic Fluorouracil Cream vs Vehicle Cream · Fisher Exact · p = <0.0001
  • Carac (Fluorouracil) Cream vs Vehicle Cream · Fisher Exact · p = <0.0001

Adverse events

Collected over Baseline up to Week 6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Generic Fluorouracil Cream1/140 (0.7%)4/140 (2.9%)21/140 (15%)
Carac (Fluorouracil) Cream0/140 (0%)1/140 (0.7%)13/140 (9.3%)
Vehicle Cream0/142 (0%)2/142 (1.4%)9/142 (6.3%)
Most frequent serious events
Most frequent serious events
EventGeneric Fluorouracil CreamCarac (Fluorouracil) CreamVehicle Cream
Urinary tract infectionInfections and infestations1/1400/1400/142
Aortic aneurysmVascular disorders1/1400/1400/142
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1400/1400/142
Inguinal hernia strangulatedGastrointestinal disorders1/1400/1400/142
BradycardiaCardiac disorders0/1401/1400/142
Aortic stenosisVascular disorders0/1400/1401/142
AstheniaGeneral disorders0/1400/1401/142
HyperhidrosisSkin and subcutaneous tissue disorders0/1400/1401/142
Most frequent other events
Showing 10 of 44
Most frequent other events
EventGeneric Fluorouracil CreamCarac (Fluorouracil) CreamVehicle Cream
NasopharyngitisInfections and infestations1/1403/1401/142
Eye IrritationEye disorders2/1400/1400/142
Application site painGeneral disorders2/1400/1400/142
HeadacheNervous system disorders2/1402/1402/142
LymphadenopathyBlood and lymphatic system disorders0/1401/1400/142
DiarrhoeaGastrointestinal disorders1/1400/1401/142
Application site dermatitisGeneral disorders1/1400/1400/142
Seasonal AllergyImmune system disorders1/1400/1400/142
CytstitisInfections and infestations1/1400/1400/142
FallInjury, poisoning and procedural complications0/1401/1400/142

Baseline characteristics

Participants who received the study drug (Safety Population).

Age, Continuous
Age, Continuous(years)Generic Fluorouracil CreamCarac (Fluorouracil) CreamVehicle CreamTotal
Mean67.7 ± 9.4667.4 ± 9.4367.1 ± 11.1367.4 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)Generic Fluorouracil CreamCarac (Fluorouracil) CreamVehicle CreamTotal
Female16182054
Male124122122368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Generic Fluorouracil CreamCarac (Fluorouracil) CreamVehicle CreamTotal
Hispanic or Latino1214
Not Hispanic or Latino139138141418
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Generic Fluorouracil CreamCarac (Fluorouracil) CreamVehicle CreamTotal
American Indian or Alaska Native1001
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White138140141419
More than one race1012
Unknown or Not Reported0000
08

Study locations

17 sites
  • Investigative Site 2
    Fremont, California, United States
  • Investigative Site 16
    Los Angeles, California, United States
  • Investigative Site 17
    San Diego, California, United States
  • Investigative Site 4
    Denver, Colorado, United States
  • Investigative Site 10
    Newnan, Georgia, United States
  • Investigative Site 5
    Boise, Idaho, United States
  • Investigative Site 1
    Arlington Heights, Illinois, United States
  • Investigative Site 11
    Buffalo Grove, Illinois, United States
  • Investigative Site 3
    Carmel, Indiana, United States
  • Investigative Site 9
    Plainfield, Indiana, United States
  • Investigative Site 6
    South Bend, Indiana, United States
  • Investigative Site 8
    Clinton Township, Michigan, United States
  • Investigative Site 13
    Warren, Michigan, United States
  • Investigative Site 12
    Fridley, Minnesota, United States
  • Investigative Site 15
    Albuquerque, New Mexico, United States
  • Investigative Site 7
    High Point, North Carolina, United States
  • Investigative Site 14
    Philadelphia, Pennsylvania, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Sep 2015, 6 months.

Results were first posted in Jul 2019, 3 years 10 months after primary completion.

Of 26 phase 3 interventional studies under Keratosis, Actinic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Nov 30, 2015
StartActual
Feb 27, 2015
Primary completionActual
Sep 17, 2015
CompletionActual
Sep 17, 2015
Results first posted
Jul 17, 2019
Last update
Jul 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02616601
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Feb 27, 2015
Primary completion
Sep 17, 2015
Completion
Sep 17, 2015
Results posted
Jul 17, 2019
Last update
Jul 17, 2019

Study contacts

Study Director
study director · Actavis Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorouracil

Start the discussion